The FDA has granted an emergency use authorization (EUA) for bamlanivimab, Lilly's COVID-19 antibody treatment. CP3 Director Dr. Walid Gellad spoke with the New York Times, and the Washington Post about this development. Gellad cautioned about the limited number of doses available as COVID cases continue to rise. He also emphasized the link between rapid, accessible testing and treatment availability. “It’s kind of the best times for these therapies to enter, because they can have an impact,” he said. “It’s also the worst time because we don’t have enough doses, and it’s going to add to the backlog of testing.”